Positive Outlook for Akero Therapeutics Based on Promising Clinical Trial Developments

Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Akero Therapeutics (AKRO – Research Report) and keeping the price target at $46.00.

Michael Ulz’s rating is based on the promising developments in Akero Therapeutics’ clinical trials, particularly the Ph3 SYNCHRONY Real-World study. The completion of patient enrollment in this study, which targets those with metabolic dysfunction-associated steatohepatitis (MASH), sets the stage for significant data readouts by the first half of 2026, providing potential catalysts for the company.

Furthermore, the upcoming 96-week data from the Ph2b SYMMETRY study, expected in February 2025, is anticipated to show additional benefits in fibrosis improvement and NASH resolution. This progress, along with the strategic alignment of their clinical programs, suggests a favorable outlook for Akero Therapeutics, underpinning Ulz’s Buy rating.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.